Treatment and prevention of dyslipidemia with cardiovascular disease
Statins are effective as primary prevention in people with risk and secondary prevention, ie in patients with manifest atherosclerotic disease character. Components of lipid metabolism play an important role in the metabolic processes of the organism adaptation to many normal and pathological conditions that lead to changes in the lipid profile. Dyslipidemia (DLP) is a part of the metabolic syndrome in many pathological conditions - diseases. DLP is not strictly specific to a particular nosology blood lipid disorders. The degree of increase in the content of individual lipid fractions determined by the severity of the pathological process and a range of metabolic adaptation of the patient. One of the most common pathological conditions associated with lipoprotein abnormalities are cardiovascular disease (CVD), the GCC is the leading cause of premature death and disability in the majority of the population, which leads to an increase in health care costs. The main objectives of the prevention of hypercholesterolemia is the elimination of the lipid metabolism (detection of cholesterol (TC) and triglycerides (TG) in the blood, low density lipoprotein (LDL) and very low density lipoproteins (VLDL) for the prevention of atherosclerosis